STAT+: Zealand’s amylin-targeting drug shows early potential in obesity
Zealand Pharma on Thursday reported early positive results of an investigational obesity drug that activates…
Category: STAT+
STAT+: Doctors Without Borders is closing its widely regarded access-to-medicines campaign
In a surprise move, Doctors Without Borders is closing down its access-to-medicines campaign, which has…
STAT+: Gilead’s twice-yearly antiviral protected women from HIV infection in large trial
Gilead said Thursday that twice-a-year injections of a new antiviral drug, called lenacapavir, completely protected…
STAT+: A primer on HELIOS-B, an enormous stock-moving event for Alnylam Pharmaceuticals
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Bold’s CEO on fall prevention, ageism in health care, and ‘movement is medicine’
BEVERLY HILLS, Calif. – When Amanda Rees was in her twenties she moved in with…
STAT+: New study bolsters evidence rare genetic mutation can delay early Alzheimer’s
For members of a large extended Colombian family, an early Alzheimer’s diagnosis is practically a…
STAT+: Novant Health calls off North Carolina hospital deal, giving a win to the FTC
Just two weeks ago, it appeared Novant Health was on the precipice of finalizing a…
STAT+: Republican lawmakers criticize FDA’s partnership with CHAI on regulating AI in medicine
Republican lawmakers are sharply criticizing the Food and Drug Administration’s relationship with a nonprofit group…
STAT+: Boston Scientific to buy vascular device maker for $1.16 billion
Boston Scientific said on Tuesday it will buy Silk Road Medical, a medical device company…
STAT+: Pharmalittle: We’re reading about a Merck pneumococcal shot, Kansas suing Pfizer, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease
A 10-person startup called Marea said Tuesday that it had raised $190 million to help…
STAT+: Freespira bets on slow and steady, amid spectacular digital health collapses
Many digital health companies have crashed and burned after promising investors speedy adoption and huge…
STAT+: To feed an AI that designs new enzymes, Basecamp hunts rare proteins at the world’s end
Not many AI companies have expeditions to the rainforest on the calendar, or need scientists…
.jpg)
STAT+: Why health care spending keeps climbing
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: Pharmalittle: We’re reading about an ‘unaffordable’ Novartis drug, a new patent office rule, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Under pressure to thwart pharma patent abuse, the PTO proposes a new rule. But will it fly?
In a bid to prevent the patent system from being abused, the U.S. Patent and…
.jpg)
STAT+: Oncologists turn to blood test for circulating tumor DNA, but questions remain on how to use the data
The hope for many cancer patients who go through surgery is that they’ll be cured…
STAT+: Why a big California employer ditched Elevance for some of its health plans
The California Public Employees’ Retirement System is making a drastic change to one of its…
STAT+: Oncologists turn to blood test for circulating tumor DNA, but questions remain on how to use the data
The hope for many cancer patients who go through surgery is that they’ll be cured…
STAT+: Colorado state board decides a pricey Novartis medicine is unaffordable
A blockbuster arthritis drug from Novartis may face a limit on what Colorado health plans…
STAT+: Biden administration to recalculate Medicare Advantage quality ratings and bonuses
The federal government is rescoring the quality ratings of this year’s Medicare Advantage plans, which…
STAT+: FDA gets pointed input on ‘optimizing’ advisory committee panels
The day an FDA advisory committee met to weigh the merits of an experimental treatment…
STAT+: Telehealth startup Done’s top leadership arrested under fraud charges
The CEO and clinical president of a closely watched telehealth startup prescribing ADHD-medication Adderall online…
STAT+: Does Sanders have the votes to subpoena a Novo exec?
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Pharmalittle: We’re reading about a Pfizer drug for Duchenne, bird flu vaccines for cows, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Will Geron be acquired? The long-short view
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried
LONDON — A major shakeup in how the benefits of medicines are assessed in Europe…
STAT+: Pfizer’s gene therapy for Duchenne muscular dystrophy fails in phase 3 trial
Pfizer said Wednesday afternoon that a closely watched gene therapy for Duchenne muscular dystrophy failed…
STAT+: New AI for biopsies can analyze microscopic images, talk to pathologists about your tumor
To non-pathologists, the histology slide looked, as all histology slides do, a sea of mottled…
STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Avidity Biosciences says its experimental drug showed potential against form of muscular dystrophy
Avidity Biosciences said Wednesday morning that an experimental medicine successfully knocked down the gene behind…
STAT+: Why Google and Microsoft can’t defuse U.S. health care’s ticking cybersecurity problem
Facing a worsening cybersecurity crisis in health care, the Biden administration has followed a familiar…
STAT+: Google’s Verily to offer GLP-1 drugs through Lightpath, its retooled chronic care app
For the second time in as many years, Google’s health tech spinout Verily is pivoting….
STAT+: Pharmalittle: We’re reading about Lilly’s Alzheimer’s drug, an EU contract for bird flu vaccine, and more
Greetings from London, with STAT reporter Andrew Joseph here filling in for Ed. We’re dealing…
STAT+: Biotech co-founded by entrepreneur Bob Langer is testing a new approach to developing obesity treatments
A new company founded by a group of biotech veterans, including Bob Langer, came out…
STAT+: Tweezers? Wrenches? Researchers plot prosthetics’ future with tools, not hands
Nearly half of people with upper-limb prosthetics abandon them. They’re often uncomfortable, dysfunctional or just…
STAT+: FDA advisers unanimously recommend approval of Eli Lilly’s Alzheimer’s disease treatment
Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval…
STAT+: Humana scores a win in a Medicare Advantage case
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: Pharmalittle: We’re reading about a Moderna Covid-flu vaccine, a paused Pfizer study, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Teladoc names insurance, finance exec as its new CEO
Virtual care company Teladoc has a new chief executive officer following the abrupt departure of…
STAT+: Moderna says data show its combination Covid-flu vaccine generates a strong immune response
Moderna announced Monday that, in a Phase 3 clinical trial, its combination Covid-19 and influenza…
STAT+: Watch: How Harvard researchers boosted an ALS patient’s independence with a box and a balloon
John Goodson practiced medicine for almost 50 years at Massachusetts General Hospital in Boston. As…
STAT+: The inside story of how Lykos’ MDMA research went awry
At a heated advisory committee meeting convened by the Food and Drug Administration last week,…
STAT+: Pharmalittle: We’re reading about Lilly’s Alzheimer’s drug, the GSK-Elsie deal, and more
Good morning, Jason Mast here filling in for Ed. Today, we’re sipping a hot cup…
STAT+: Stephen Quake on the Chan Zuckerberg quest to cure, prevent, or manage all diseases by 2100
SAN DIEGO — Decades ago, as a young physics Ph.D. student, Stephen Quake stumbled into…
STAT+: At BIO, signs Congress’ tough stance on China is chilling biotech relationships
SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese…
STAT+: Cigna wins case to block former executive from jumping to CVS
CVS Health viewed Amy Bricker as a potential CEO. But she won’t be going to…
STAT+: FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted to a smaller group
Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental…
STAT+: Pharmalittle: We’re reading about the aftermath of FDA vote on MDMA, rising pharma layoffs, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Psychedelics companies see FDA panel’s vote as a growth opportunity, not a roadblock
A day after a panel of advisers to the Food and Drug Administration expressed deep…